- Liberta RC™ deep brain stimulation (DBS) system, recently
approved by the U.S. FDA, features NeuroSphere™ Virtual Clinic,
which allows for remote programming of the system
- System offers the longest time between charges of any DBS
technology on the market, allowing people with movement disorders
to recharge the device only 10 times a year2*
ABBOTT
PARK, Ill., Jan. 25,
2024 /PRNewswire/ -- Abbott (NYSE: ABT) announced
today that it received approval from the U.S. Food and Drug
Administration (FDA) to launch the Liberta RC™ DBS system, the
world's smallest rechargeable deep brain stimulation (DBS) device
with remote programming, to treat people living with movement
disorders.1+ The Liberta RC DBS system
also requires the fewest recharges of any FDA-approved DBS system,
needing only 10 recharge sessions a year for most
people.2*
Communication between people and their doctors is critical to
ensuring exceptional care, especially for those who suffer from
chronic conditions, such as Parkinson's disease and essential
tremor, that can be treated with deep brain stimulation therapy.
The Liberta RC DBS system is the only rechargeable DBS device
compatible with Abbott's proprietary NeuroSphere™ Virtual Clinic, a
first-of-its-kind connected care technology in the U.S. that allows
people to communicate with their doctors, ensure proper settings
and functionality, and receive new treatment settings remotely as
needed without stepping foot in a doctor's office.^ Abbott
developed NeuroSphere Virtual Clinic after research showed that the
average Abbott DBS user in the U.S. must travel more than 150 miles
to access a movement disorder specialist.3
"When our patients choose a rechargeable DBS system, it is often
based on the smaller size of the device, but the tradeoff has
always been how recharge frequency affects their lifestyle," said
Dr. Paul Larson, professor of
neurosurgery at the University of
Arizona. "The Liberta RC DBS system excels in both areas, as
a compact rechargeable device with the lowest recharge requirement
of any FDA-approved DBS system. This achievement, coupled with the
integration of remote programming capabilities, is a significant
advancement for patients."
At approximately the height and width of a smartwatch face, the
Liberta RC DBS system is about 31% smaller than other commonly used
implantable, rechargeable DBS devices currently available in the
U.S.4** When used under standard settings, Abbott's
Liberta RC DBS system needs to be recharged as few as every 37 days
– or 10 times a year – using a wireless charger that is placed over
the device.5 For users who prefer a weekly charging
schedule, only 30 minutes of charging is needed.5 The
wireless charging system allows people to be active while wearing
it and can fully recharge the Liberta RC DBS system twice before
needing to be plugged in again.6 The system, which can
be controlled on an Abbott supplied patient controller or a
compatible and secure iOS device***, offers users helpful
notifications and customizable settings for a personalized charging
experience.
"In developing the Liberta RC DBS system, our focus has been on
the unique experiences of individuals with chronic conditions like
movement disorders," said Pedro Malha, vice president,
neuromodulation, Abbott. "At Abbott, we're committed to addressing
these diverse needs. This system exemplifies our drive to providing
patient-first solutions, combining effective therapy, effortless
recharging, and remote programming capabilities."
For U.S. important safety information on the Abbott Liberta RC
DBS neurostimulation system, visit: https://bit.ly/DBSISI
+Based off comparison to volumetric measurements,
including the following IPGs: Abbott Liberta RC DBS System: 13.79
cc, SceneRay Aaxon RNDǂ: 24 cc, and PINS G102Rǂ: 31.5 cc.
*Upon implant of the Liberta RC DBS System, 37 days of therapy when
programmed with standard (nominal) stimulation settings as
described in device Instructions for Use (IFU). Recommended
recharge frequency and duration for competitor rechargeable DBS
systems described in their respective IFU or clinical studies,
which may involve different patient populations and other
variables. Not a head-to-head comparison of stimulation settings or
clinical outcomes.
^Anywhere with a cellular or Wi-Fi connection and sufficiently
charged patient controller and neurostimulation device.
**Calculated by comparing the Liberta RC DBS System vs. the Boston
Scientific Vercise‡ Genus R16 based on volumetric measurements
(13.79cc for Liberta RC DBS System and 20.1cc for Boston Scientific
Vercise‡ Genus).
***Available on eligible smart mobile digital devices. For a list
of personal smart mobile digital devices compatible with Abbott's
patient controller app, visit
http://www.NMmobiledevicesync.com/dbs.
About Abbott
Abbott is a global healthcare leader that
helps people live more fully at all stages of life. Our portfolio
of life-changing technologies spans the spectrum of healthcare,
with leading businesses and products in diagnostics, medical
devices, nutritionals and branded generic medicines. Our 114,000
colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com and
on LinkedIn, Facebook, Instagram, X and YouTube.
1 Abbott. Liberta RC™ DBS System Remote Programming
Comparison Claims Memo. Plano, TX.
2024.
2 Abbott. Liberta RC™ DBS System Recharging Comparison
Claims Memo. Plano, TX. 2024.
3 Abbott. DBS Patient Travel Memo. MAT-2100238 V1.0.
4 Abbott. Liberta RC™ DBS System Size Comparison Claims
Memo. Plano, TX. 2024.
5 Abbott. Liberta RC™ Deep Brain Stimulation Implantable
Pulse Generator Clinician's Manual. Plano, TX. 2023.
6 Abbott. Jupiter Software Formula Specification.
Plano, TX. 2023.
View original
content:https://www.prnewswire.com/news-releases/abbott-launches-worlds-smallest-rechargeable-system-with-remote-programming-capabilities-to-treat-movement-disorders-302044404.html
SOURCE Abbott